Alto neuroscience initiates phase 2 study of alto-101, a novel pde4 inhibitor, in cognitive impairment associated with schizophrenia

Los altos, calif.--(business wire)--alto neuroscience, inc. (“alto”) (nyse: anro) today announced the initiation of a phase 2 double-blind, placebo-controlled study of its transdermal formulation of alto-101, a novel pde4 inhibitor in development for the treatment of cognitive impairment associated with schizophrenia (cias). alto expects to report top-line data from the phase 2 study in the second half of 2025. “we are excited to initiate our sixth phase 2 study as a company, across our pipelin.
ALTO Ratings Summary
ALTO Quant Ranking